Surfactant replacement therapy

Clinics in Chest Medicine

Volumn 21, Issue 3, 2000, Pages 531-541

  Spragg, Roger G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTIFICIAL LUNG SURFACTANT; LUNG SURFACTANT; LUNG SURFACTANT EXTRACT;

ACUTE RESPIRATORY TRACT DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTIFICIAL VENTILATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ALVEOLUS SURFACE TENSION; LUNG FUNCTION TEST; META ANALYSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SWINE;

EID: 0033796504     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-5231(05)70164-7     Document Type: Article

References (63)

1. Inhibition of the human neutrophil respiratory burst by native and synthetic surfactant
2. Aerosolized surfactants in adults with sepsis-induced acute respiratory distress syndrome
3. Acute respiratory distress in adults
4. Damage to surfactant-specific protein in acute respiratory distress syndrome
5. Lavage administration of dilute surfactants after acute lung injury in neonatal piglets
6. Functions of the alveolar lining
7. 4-surfactant in preterm infants with respiratory distress syndrome
8. Efficacy and standardization of SF-RI 1: A preparation from bovine lung surfactant
9. Effects of a protein-free, synthetic surfactant on survival and pulmonary function in preterm lambs
10. Surfactant replacement attenuates the increase in alveolar permeability in hyperoxia
11. Artificial surfactant therapy in hyaline-membrane disease
12. Exposure of the hydrophobic components of porcine lung surfactant to oxidant stress alters surface tension properties
13. Effect of volume and dose on the pulmonary distribution of exogenous surfactant administered to normal rabbits or to rabbits with oleic acid lung injury
14. Bronchoalveolar lavage with a diluted surfactant suspension prior to surfactant instillation improves the effectiveness of surfactant therapy in experimental acute respiratory distress syndrome (ARDS)
15. Bovine surfactant therapy for patients with acute respiratory distress syndrome
16. Surfactant chemical compositor and biophysical activity in acute respiratory distress syndrome
17. Surfactant alterations in severe pneumonia, acute respiratory distress syndrome, and cardiogenic lung edema
18. Mechanisms of peroxynitrite induced injury to pulmonary surfactant
19. Inhibition of alveolar type II cell ATP and surfactant synthesis by nitric oxide
20. Comparison of rSP-C surfactant with natural and synthetic surfactants after late treatment in a rat model of the acute respiratory distress syndrome
21. Isolation of human surfactant from amniotic fluid and a pilot study of its efficacy in respiratory distress syndrome
22. Evidence of lung surfactant abnormality in respiratory failure: Study of bronchoalveolar lavage phospholipids, surface activity, phospholipase activity, and plasma myoinositol
23. Exogenous surfactant and nitric oxide have a synergistic effect in improving gas exchange in experimental ARDS
24. Surfactant inactivation in adult respiratory distress syndrome
25. Inhibition of pulmonary surfactant function by phospholipases
26. Artificial surfactant attenuates hyperoxic lung injury in primates. I. Physiology and biochemistry
27. Effects of ventilation strategies on the efficacy of exogenous surfactant therapy in a rabbit model of acute lung injury
28. Lachmann B: Surfactant replacement in acute respiratory failure: Animal studies and first clinical trials. In Lachrnann B (ed): Surfactant Replacement Therapy. New York, Springer-Verlag, 1987, pp
29. In vivo lung lavage as an experimental model of the respiratory distress syndrome
30. Exogenous surfactant therapy for pediatric patients with the acute respiratory distress syndrome
31. Nebulized vs. instilled exogenous surfactant in an adult lung injury model
32. Aerosolized surfactant is preferentially deposited in normal versus injured regions of lung in a heterogeneous lung injury model
33. Dosing and delivery of a recombinant surfactant in lung-injured adult sheep
34. Aerosolized surfactant improves pulmonary function in endotoxin-induced lung injury
35. Elastase and α 1-proteinase inhibitor activity in tracheal aspirates during respiratory distress syndrome. Role of inflammation in the pathogenesis of bronchopulmonary dysplasia
36. Dry artificial lung surfactant and its effect on very premature babies
37. Exogenous surfactant and partial liquid ventilation: Physiologic and pathologic effects
38. Surfactant for adults with respiratory failure
39. Mitigation of injury in canine lung grafts by exogenous surfactant therapy
40. Surfactant abnormalities in patients with respiratory failure after multiple trauma
41. Compositional, structural, and functional alterations in pulmonary surfactant in surgical patients after the early onset of systemic inflammatory response syndrome or sepsis
42. Alveolar and tissue surfactant pool sizes in humans
43. Intrapulmonary catabolism of surfactant-saturated phosphatidylcholine in rabbits
44. Albuminous expectoration following thoracocentesis
45. Clinical trials of natural surfactant phospholipids in the treatment of the neonatal respiratory distress syndrome (RDS)
46. Ultrasonic nebulization for efficient delivery of surfactant in a model of acute lung injury. Impact on gas exchange
47. Alteration of surfactant function due to protein leakage: Special interaction with fibrin monomer
48. Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome (Cochrane Review). The Cochrane Library [Cochrane Database of Systematic Reviews]
49. Neutrophil elastase and acute pulmonary damage in neonates with severe respiratory distress syndrome
50. Acute effects of a single dose of porcine surfactant on patients with the adult respiratory distress syndrome
51. Artificial surfactant (surfactant TA) modulates adherence and superoxide production of neutrophils
52. Altered surface tension of lung extracts and lung mechanics
53. Pulmonary surfactant subfractions in patients with the acute respiratory distress syndrome
54. Bronchoscopic surfactant administration in patients with severe adult respiratory distress syndrome and sepsis
55. Safety and efficacy of an aerosolized surfactant (Exosurf) in human sepsis-induced ARDS
56. Effects of TNF-α and phorbol ester on human surfactant protein and MnSOD gene transcription in vitro
57. A multicenter trial in human sepsis-induced ARDS of an aerosolized synthetic surfactant (Exosurf)
58. Calf's lung surfactant extract in acute hypoxemic respiratory failure in children
59. Perfluorochemical rescue after surfactant treatment: Effect of perflubron dose and ventilatory frequency
60. Immunomodulatory functions of surfactant
61. Bovine pulmonary surfactant: Chemical composition and physical properties
62. Combined surfactant therapy and inhaled nitric oxide in rabbits with oleic acid-induced acute respiratory distress syndrome
63. Nitration of surfactant protein A (SP-A) tyrosine residues results in decreased mannose binding ability